SynthesisInternational journal of molecular sciences2026
The Efficacy of Mesenchymal Stem Cell Therapy in Large Animal Models of Acute Liver Failure: A Meta-Analysis.
Synthesis in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic senolytic-regenerative therapy significantly extends healthspan and lifespan.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Mesenchymal stem cells (MSCs) show therapeutic effects for acute liver failure (ALF), as demonstrated in small animal models of ALF, which showed improved survival and liver function. Nevertheless, small animal models are limited by their simplified immune systems and lower pathophysiological complexity, which prevent them from fully capturing the key features of human ALF. Large animal models offer better physiological similarity; however, the effectiveness of MSC therapy on large animal models of ALF, such as pigs and monkeys, remains unclear. In this study, we performed a meta-analysis to comprehensively evaluate the therapeutic effect and safety of MSC therapy in large animal models of ALF. A comprehensive search was conducted across PubMed/Medline, Web of Science, Embase, and the Cochrane Library for studies published prior to 3 March 2025. Of the 609 identified studies, 13 were included, with the majority showing a low or unclear risk of bias. The results of the meta-analysis indicated that MSC therapy was associated with a higher survival rate and lower levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in large animal models with ALF, compared with the control groups. Subgroup analyses showed efficacy in both pig and monkey models. Furthermore, they showed that bone marrow-derived mesenchymal stem cells and the deep vein transplantation route were each linked to a significantly higher survival rate and to lower ALT and AST levels after treatment in pigs with ALF. Additionally, a dose of (3.0-3.3) × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.